Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study, was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26. The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia.

In the study, 533 patients received high-flux hemodialysis and were compared to 559 patients who received HDx therapy. HDx therapy targets the efficient removal of large-middle molecules, allowing for filtration closer to that of the natural kidney. Many of these large-middle molecule uremic toxins have been linked to the development of inflammation, cardiovascular disease, and other comorbidities in dialysis patients.

HDx therapy uses Baxter?s Theranova dialyzer equipped with the MCO membrane, which filters a wider range of middle molecule uremic toxins from the blood, specifically targeting the large-middle molecules not effectively removed by conventional hemodialysis therapies. In addition to its clearance profile, HDx therapy enabled by Theranova dialyzer is as simple to perform as conventional hemodialysis (HD) and was designed to work with all HD machines. This allows clinics to offer HDx therapy using existing resources and eliminates the need for special equipment and added clinic workflow, which is required for HDF.